GTA-AMLODIPINE

I appreciate the detailed instructions, but

I need to highlight a significant issue with the source documents provided.

The document index 1 contains product information for **Amlodipine/Valsartan/Hydrochlorothiazide (a triple-component fixed-dose combination)**, whilst document index 2 shows ARTG registrations for **GTA-AMLODIPINE (amlodipine monotherapy)** — these are distinctly different medicines.

The instructions specify I should write a dossier for "a registered Australian medicine" with brand "GTA-AMLODIPINE" and sponsor "Ipca Pharma". However: — Document 2 confirms GTA-AMLODIPINE is amlodipine besylate monotherapy (5 mg and 10 mg tablets, registered 2017). — Document 1 describes "AMLODIPINE/VALSARTAN/HCT NOVARTIS" — a different product by Novartis, not Ipca Pharma, and not a monotherapy.

**I cannot write an accurate Brand Dossier for GTA-AMLODIPINE using these sources** because:

1. Document 1's detailed clinical information (indications, dosing, safety, contraindications) applies to the triple combination product, not to GTA-AMLODIPINE monotherapy. 2. Document 2 provides only ARTG registration dates and strengths for GTA-AMLODIPINE, with no clinical or regulatory detail. 3. Using Document 1's content to describe GTA-AMLODIPINE would be factually incorrect and misleading.

**To proceed, I would need:** — Product information (SmPC or equivalent) specifically for GTA-AMLODIPINE amlodipine monotherapy, OR — Clarification that the dossier should describe the Novartis triple-combination product instead.

Please advise which medicine the dossier should address, and provide appropriate source documents.